Lacerta Therapeutics
Shannon Wilson has over 13 years of experience in Accounting & Finance. She started her career in public accounting as an auditor, where she conducted financial audits of various industries. She has extensive experience in financial reporting and in federal and state compliance. Prior to joining Lacerta, Shannon was the Director of Finance for a local school district. She helped manage a budget of more than $100 million, including federal and state grants, allocated across eighteen schools and twenty departments. She was also in charge of the preparation and submission of annual financial reporting to the Department of Education, School Board, and State Auditor General’s Office. She received her MBA with a concentration in Accounting from Saint Leo University.
This person is not in any teams
This person is not in any offices
Lacerta Therapeutics
Lacerta Therapeutics is a clinical stage gene therapy company using a constellation of proprietary adeno-associated virus (AAV) vector technologies to develop treatments for central nervous system and lysosomal storage diseases. With unmatched scientific expertise and depth in the development, production, and application of AAV vectors, LacertaTherapeutics is advancing its clinical programs using its proprietary capsid variants and scalable vector manufacturing platform. The experience and accomplishments of the Lacerta Therapeutics founders are unsurpassed in AAV gene therapy. In addition to world-class basic AAV vector development and gene therapy clinical trial expertise, our team brings to bear individuals with novel insight into developing novel, targeted neurological and lysosomal storage disease treatments.